In August, researchers published an updated review of data from a 2021 study in the U.K. on medRxiv, a preprint service for medical research. The original study conducted by the U.K. National Health Service (NHS) examined 44 children aged 12 to 15 over three years who were prescribed puberty-blocking drugs to treat gender dysphoria. Participants took triptorelin, a prostate cancer medicine used to inhibit the synthesis of estrogen in women and testosterone in men.

According to researchers at the University of Essex, the mental health of between 20 and 34 percent of participants significantly deteriorated over the course of treatment. Just between 9 and 20 percent reported a reliable improvement. Between 56 and 68 percent witnessed no change in distress.

In other words, less than a fifth of those prescribed puberty-blocking drugs, if that, experienced emotional improvement following treatment. The findings contradict broad claims that such medical interventions are necessary to save gender-confused children from the perils of suicidal ideation.

[It’s good to see some actual science on this, but don’t expect it to have much impact. The trans movement, especially in relation to minors, is not based on science. It’s a cult, and it uses cult tactics to recruit members and defend itself against critics. — Ed]